ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Small-Cell Lung Cancer in St Louis, MO

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Colorectal Cancer
Cancer
Squamous Cell Carcinoma of Head and Neck
Neoplasm Metastasis
Melanoma

Non-Small-Cell Lung Cancer trials near St Louis, MO, USA:

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients , Non...

Enrolling
Renal Cell Carcinoma (RCC)
Small Cell Lung Cancer
Drug: AL8326 40 mg
Drug: AL8326 60 mg

Phase 2

Advenchen

St Louis, Missouri, United States and 6 other locations

Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features (NEO-SURG)

followed by resection and adjuvant cemiplimab in stage 3 non-small cell lung cancer (NSCLC) with select ...

Enrolling
Non-small Cell Lung Cancer Stage III
Drug: Cemiplimab-Rwlc

Phase 2

Georgetown University
Georgetown University

St Louis, Missouri, United States and 2 other locations

First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (FLINN)

This is a single center, phase Ib/II study combining an anti-PD-1 antibody and an anti-CTLA-4 antibody with IL-15. It is testing the hypothesis that...

Enrolling
Non-small Cell Lung Cancer Stage IV
Non-small Cell Lung Cancer Recurrent
Drug: Nivolumab
Drug: Ipilimumab

Phase 1, Phase 2

The Washington University
The Washington University

St Louis, Missouri, United States

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

HCC is a common cancer worldwide and a leading cause of cancer-related death. Lung cancer is the most frequently ...

Enrolling
Hepatocellular Cancer
Squamous-Cell Non-Small Cell Lung Cancer
Drug: ABBV-324
Drug: Lenvatinib

Phase 1

AbbVie
AbbVie

St Louis, Missouri, United States and 21 other locations

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (LIVIGNO-4)

Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mort...

Enrolling
Non-Small Cell Lung Cancer
Drug: Carboplatin
Drug: Livmoniplimab

Phase 2, Phase 3

AbbVie
AbbVie

St Louis, Missouri, United States and 61 other locations

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (CHRYSALIS)

combination with standard of care carboplatin and pemetrexed) in 21 day treatment cycle for participants with advanced non-small c ...

Active, not recruiting
Non-Small-Cell Lung Cancer
Drug: Amivantamab
Drug: Carboplatin

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

St Louis, Missouri, United States and 71 other locations

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the-...

Enrolling
Non-small Cell Lung Cancer
Drug: Nab-paclitaxel
Drug: Pembrolizumab

Phase 3

AstraZeneca
AstraZeneca

Bridgeton, Missouri, United States and 311 other locations

Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

In this study, patients with metastatic non-small cell lung cancer that is EGFR-mutated, who have receiv...

Active, not recruiting
Metastatic Non Small Cell Lung Cancer
Drug: Osimertinib
Drug: APL-101

Phase 1, Phase 2

The Washington University
The Washington University

St Louis, Missouri, United States

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Telisotuzumab vedotin

Phase 2

AbbVie
AbbVie

St Louis, Missouri, United States and 254 other locations

Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

of zimberelimab, domvanalimab, and etrumadenant in patients with non-small cell lung cancer previously t...

Active, not recruiting
Non-small Cell Carcinoma
Non-small Cell Lung Cancer
Drug: Zimberelimab
Drug: Domvanalimab

Phase 2

The Washington University
The Washington University

St Louis, Missouri, United States

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems